Structural basis for the signal transduction of erythropoietin

  • Timothy D. Osslund
Part of the Milestones in Drug Therapy book series (MDT)


The structures of recombinant erythropoietin (r-HuEPO), the extracellular ligand-binding portion of erythropoietin receptor (EPOR) and several novel peptides have been extensively studied using a variety of methods including X-ray crystallography and nuclear magnetic resonance (NMR) [1, 2] The receptor for EPO has been classified as a member of the class 1 cytokine receptor super family [3, 4]. EPOR is a transmembrane receptor that is activated when EPO binds to the extracellular portion of the receptor causing dimerization [5]. The dimerization of the extracellular portion of the receptor induces tyrosine kinase proteins associated with the cytoplasmic side of the receptor to initiate the signal transduction events that eventually cause the committed erythroid-colony-forming units (CFU-E) progenitor cells to eventually mature into red blood cells [6] (Fig. 1).


Darbepoetin Alfa Nuclear Magnetic Resonance Structure Erythropoietin Receptor Signal Transduction Event Extracellular Portion 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Syed RS, REid SW, Li C et al. Efficiency of signalling through cytokine receptors depends critically on receptor orientation. Nature 1998;395:511–516.PubMedCrossRefGoogle Scholar
  2. 2.
    Cheetham JC, Smith DM, Aoki KH et al. NMR structure of human erythropoietin and a comparison with its receptor bound conformation. Nat Struct Mol Biol 1998;5:861–866.CrossRefGoogle Scholar
  3. 3.
    Bazan JF. Structural design and molecular evolution of a cytokine receptor superfamily. Proc Natl Acad Sci USA 1990;87:6934–6938.PubMedCrossRefGoogle Scholar
  4. 4.
    D’Andrea AD, Lodish HF, Wong GG. Expression cloning of the murine erythrorpoietin receptor. Cell 1989;57:277–285.PubMedCrossRefGoogle Scholar
  5. 5.
    Philo JS, Aoki KH, Arakawa T et al. Dimerization of the extracellular domain of the erythropoietin (EPO) receptor by EPO: One high-affinity and one low-affinity interaction. Biochemistry 1996;35:1681–1691.PubMedCrossRefGoogle Scholar
  6. 6.
    Damen JEK, Krystal G. Early events in erythropoietin-induced signalling. Exp Hematol 1996;24:1455–1459.PubMedGoogle Scholar
  7. 7.
    Yoshimura A, Longmore G, Lodish HF. Point mutation in the exoplasmic domain of the erythropoietin receptor resulting in hormone-independent activation and tumorigenicity. Nature 1990;348:647–649.PubMedCrossRefGoogle Scholar
  8. 8.
    Elliott S, Lorenzini T, Yangihara D et al. Activation of the erythropoietin (EPO) receptor by bivalent anti-EPO receptor antibodies. J Biol Chem 1996;271:24691–24697.PubMedCrossRefGoogle Scholar
  9. 9.
    Wrighton NC, Farrell FX, Johnson DL et al. Small peptides as potent mimetics of the protein hormone erythropoietin. Science 1996;273:458–463.PubMedCrossRefGoogle Scholar
  10. 10.
    Livnah O, Stura EA, Johnson DL et al. Functional mimicry of a protein hormone by a peptide agonist: The EPO receptor complex at 2.8 A. Science 1996;273:464–471.PubMedCrossRefGoogle Scholar
  11. 11.
    Wrighton NC, Balasubramanian P, Barbone FP et al. Increased potency of an erythropoietin peptide mimetic through covalent dimerization. Nat Biotech 1997;15:1261–1265.CrossRefGoogle Scholar
  12. 12.
    Naranda T, Wong K, Kaufman RI et al. Activation of erythropoietin receptor through a novel extracellular binding site. Endocrinology 2002;143:2293–2302.PubMedCrossRefGoogle Scholar
  13. 13.
    Constantinescu SN, Keren T, Socolovsky M et al. Ligand-independent oligomerization of cell-surface erythropoietin receptor is mediated by the transmembrane domain. Proc Natl Acad Sci USA 2001;98:4379–4384.PubMedCrossRefGoogle Scholar
  14. 14.
    Macdougall IC, Eckardt K-U. Novel strategies for stimulating erythropoiesis and potential new treatments for anaemia. The Lancet 2006;368:947–953.CrossRefGoogle Scholar
  15. 15.
    Jarsch, M, Brandt M, Lanzendorfer M et al. Comparative erythropoietin receptor binding kinetics of C.E.R.A. and epoetin-b determined by surface plasmon resonance and competition binding assay. Pharmacology 2008;81:63–69.PubMedCrossRefGoogle Scholar
  16. 16.
    Molineux G. The design and development of pegfilgrastim (PEG-rmetHuG-CSF, Neulasta). Curr Pharmaceut Design 2004;10:1235–1244.CrossRefGoogle Scholar
  17. 17.
    Harris JM, Martin NE, Modi M. Pegylation: a novel process for modifying pharmacokinetics. Clin Pharmacokinetics 2001;40:539–551.CrossRefGoogle Scholar
  18. 18.
    Narhi LO, Arakawa T, Aoki K et al. Asn to Lys mutations at three sites which are N-glycosylated in the mammalian protein decrease the aggregation of Escherichia coli-derived erythropoietin. Protein Eng 2001;14:135–140.PubMedCrossRefGoogle Scholar
  19. 19.
    Ibrahimi OA, Yeh BK, Eliseenkova AV et al. Analysis of mutations in fibroblast growth factor (FGF) and a pathogenic mutation in FGF receptor (FGFR) provides direct evidence for the symmetric two-end model for FGFR dimerization. Mol Cell Biol 2005;25:671–684.PubMedCrossRefGoogle Scholar
  20. 20.
    Hill CP, Osslund TD, Eisenberg D. The structure of granulocyte colony-stimulating factor and its relationship to other growth factors. Proc Natl Acad Sci USA 1993;90:5167–5171.PubMedCrossRefGoogle Scholar
  21. 21.
    Bazan JF. Haemopoietic receptors and helical cytokines. Immunol Today 1990;11:350–354.PubMedCrossRefGoogle Scholar
  22. 22.
    Hilton DJ, Watowich SS, Katz L et al. Saturation mutagenesis of the WSXWS motif of the erythropoietin receptor. J Biol Chem 1996;271:4699–4708.PubMedCrossRefGoogle Scholar
  23. 23.
    Philo JS, Wen J, Wypych J et al. Human stem cell factor dimer forms a complex with two molecules of the extracellular domain of its receptor, kit. J Biol Chem 1996;271:6895–6902.PubMedCrossRefGoogle Scholar
  24. 24.
    Barbone EP, Middleton SA, Johson DL et al. Mutagenesis studies of the human erythropoietin receptor. Establishment of structure-function relationships. J Biol Chem 1997;272:4985–4992.PubMedCrossRefGoogle Scholar
  25. 25.
    Wen D, Bossiel JP, Tracy TE et al. Erythropoietin structure-function relatioships: high degree of sequence homology among mammals. Blood 1993;82:1507–1516.PubMedGoogle Scholar

Copyright information

© Birkhäuser Verlag/Switzerland 2009

Authors and Affiliations

  • Timothy D. Osslund
    • 1
  1. 1.Analytical and Formulation ScienceAmgen Inc.Thousand OaksUSA

Personalised recommendations